<DOC>
	<DOCNO>NCT00287092</DOCNO>
	<brief_summary>Pediacel™ currently license UK use 3 dose regimen active immunisation infant Diphtheria , Tetanus , Pertussis , Poliomyelitis invasive infection cause Haemophilus influenzae type b . However currently clinical data support use Pediacel™ use 3 , 5 , 12 month age vaccination schedule . This study design provide safety immunogenicity data support use Pediacel™ accord 3 , 5 , 12 month schedule .</brief_summary>
	<brief_title>Comparison Safety Immunogenicity Pediacel™ Infanrix™ IPV+Hib ( Penta ) Given 3 Dose Schedule Infants</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infants age 80 120 day inclusive day inclusion . Born full term pregnancy ( &gt; 37 week ) Informed consent form sign parent ( ) legal representative accord local regulation Parent ( ) legal representative able attend schedule visit understand comply study procedure ( able read write ; access telephone ) . Rectal temperature ≥ 38.0°C Moderate severe acute illness without fever Participation another clinical trial 4 week precede first trial vaccination Having receive DTaP , IPV , Hib vaccines prior study initiation vaccination 4 week precede first trial vaccination Planned participation another clinical trial present trial period Known history diphtheria , tetanus , pertussis , H. influenzae type b infection , poliomyelitis Congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Systemic hypersensitivity vaccine component ( include neomycin , streptomycin , polymyxin B formaldehyde ) History lifethreatening reaction ( encephalopathy , Hypotonic Hyporesponsive Episode , severe fever , convulsion , etc . ) trial vaccine vaccine contain substance Blood bloodderived product ( immunoglobulin ) receive past 4 week Vaccination plan 6 week follow trial vaccination Known HIV seropositivity Thrombocytopenia bleed disorder contraindicate intramuscular vaccination History seizures progressive , evolve unstable neurological condition Clinically significant finding review system might interfere correct vaccination , opinion Investigator , would interfere evaluation vaccine pose health risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>80 Days</minimum_age>
	<maximum_age>120 Days</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Haemophilus influenzae type b ;</keyword>
	<keyword>Corynebacterium diphtheriae ;</keyword>
	<keyword>Clostridium tetani ;</keyword>
	<keyword>Bordetella pertussis ;</keyword>
	<keyword>poliovirus type 1 , 2 3 ;</keyword>
	<keyword>Vero cell ;</keyword>
	<keyword>Influenza ;</keyword>
	<keyword>Diphtheria</keyword>
</DOC>